Courier Capital LLC Has $2 Million Position in Boston Scientific Co. (NYSE:BSX)

Courier Capital LLC raised its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 108.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,384 shares of the medical equipment provider's stock after buying an additional 11,661 shares during the quarter. Courier Capital LLC's holdings in Boston Scientific were worth $1,999,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Boston Scientific by 4.4% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock worth $345,205,000 after acquiring an additional 173,034 shares in the last quarter. HWG Holdings LP purchased a new stake in shares of Boston Scientific during the 2nd quarter worth about $482,000. Principal Financial Group Inc. lifted its holdings in shares of Boston Scientific by 5.9% during the 3rd quarter. Principal Financial Group Inc. now owns 2,010,441 shares of the medical equipment provider's stock valued at $168,475,000 after buying an additional 111,724 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Boston Scientific by 0.9% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,456,741 shares of the medical equipment provider's stock valued at $289,675,000 after buying an additional 30,636 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in Boston Scientific by 153.5% in the third quarter. Intech Investment Management LLC now owns 197,387 shares of the medical equipment provider's stock worth $16,541,000 after buying an additional 119,525 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Down 0.1 %

Shares of BSX stock traded down $0.10 during trading hours on Monday, reaching $94.78. The company had a trading volume of 4,213,238 shares, compared to its average volume of 5,358,167. The company has a 50 day moving average of $89.96 and a 200 day moving average of $83.89. The firm has a market cap of $139.69 billion, a price-to-earnings ratio of 78.33, a P/E/G ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 1-year low of $59.61 and a 1-year high of $97.13.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's revenue for the quarter was up 19.3% on a year-over-year basis. During the same period last year, the company posted $0.50 EPS. On average, equities research analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares in the company, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 4,119 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares of the company's stock, valued at $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,989 shares of company stock valued at $2,702,261. Company insiders own 0.50% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research report on Friday. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Wells Fargo & Company boosted their price target on Boston Scientific from $98.00 to $100.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Sanford C. Bernstein increased their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Finally, Stifel Nicolaus boosted their target price on Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and a consensus price target of $97.26.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.